CD8A and neoplasm: Our data showed that intratumoral injection of CCL5 into MC38 tumors might enhance the fraction of CD8+ T cells positive for the CCL5 receptor CCR5, could increase intratumoral levels of mature CD11b+ NK cells, and in combination with an otherwise ineffective dose of anti-PD-L1, limited tumor progression.